Changing the trajectory of chronic metabolic disease: the evolving role of GLP-1-based care
Chair: Alice Cheng (CAN) 18:45 – 18:50 Welcome and introduction Alice Cheng (CAN) 18:50 – 19:10 More than weight loss: focusing on outcomes that matter
Chair: Alice Cheng (CAN) 18:45 – 18:50 Welcome and introduction Alice Cheng (CAN) 18:50 – 19:10 More than weight loss: focusing on outcomes that matter
Chair: W. Timothy Garvey (USA) 12:15 – 12:17 Welcome and introduction W. Timothy Garvey (USA) 12:17 – 12:38 Amylin in action: from mechanisms to meaningful
Chair: Carel Le Roux (IRL) 17:45 – 17:50 Opening perspectives: framing the amylin story Carel Le Roux (IRL) 17:50 – 18:05 Amylin biology in action:
Chair: Jaime Almandoz (USA) 18:00 – 18:10 Opening the conversation on modern obesity treatments Jaime Almandoz (USA) 18:10 – 18:35 Oral and injectable semaglutide: weight
Chair: Alice Cheng (CAN) 16:15 – 16:18 Welcome and introduction Alice Cheng (CAN) 16:18 – 16:24 Why is MASH underdiagnosed? Alice Cheng (CAN) &
Chairs: Chantal Mathieu (BEL) & Zoe Williams (GBR) 09:00 – 09:15 Welcome and introduction: intergrating a person-centred approach to cardimetabolic diseases Chantal Mathieu (BEL)Zoe